Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVXGA (CVXGA50) Intranasal COVID-19 Vaccine vs COMIRNATY in Adults
NCT06742281Phase 2Completed
- Sponsor
- CyanVac LLC
- Start
- Dec 2024
- Primary completion
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CVXGA in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by CyanVac LLC. Primary endpoint: Percentage of participants with symptomatic COVID-19. Started Dec 2024; status: completed.
02
Drugs
CVXGA
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06742281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06742281.